Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
- Greece agrees on budget plan - Spain a concern as Catalonia in need of aid - Markets look ahead to Jackson Hole meeting The Footsie remained firmly in the red in morning trade as concerns over the Eurozone and speculation about the upcoming Jackson Hole meeting in Wyoming continue to be the focus
Read more- Spain a concern as Catalonia needs aid - Markets await Bernanke - Ex-div Glencore a heavy faller early on Ex-div stocks and miners were weighing heavily on the FTSE 100 index in early trading on Wednesday morning with worries about Spain weighing on sentiment. It was revealed yesterday that the
Read moreAstraZeneca: JPMorgan Cazenove downgrades to underweight, target lifted from 2,800p to 2,970p. Balfour Beatty: JPMorgan Cazenove downgrades to neutral. Barclays: Citigroup reiterates buy and 330p target price. ENRC: Credit Suisse downgrades to neutral, target cut from 500p to 450p. FirstGroup: J
Read moreWhat a difference a year makes, Tempus in The Times proclaims. When the Arab Spring was in full flow, investors worried that Hikma Pharmaceuticals was too exposed to the unstable region. The company, based in Jordan, almost halved last year's sales growth forecast as governments fell. Now it looks w
Read moreUBS has cut its target price for mining group Eurasian Natural Resources Corp (ENRC) from 585p to 565p after first-quarter figures came in below expectations. UBS has reduced its 2012 and 2013 EPS estimates by 4% and 7%, respectively, mainly on the back of a higher tax rate (which moderates from 20
Read more- UK retail sales beat estimates in July - Investors eye US data - Chinese stimulus hopes increase After a pretty subdued start, the Footsie had fallen further into the red by Thursday lunchtime in spite of some better-than-expected UK retail sales data. Sales volumes rose by 0.3% during July, up
Read moreJefferies has maintained its 'buy' rating and 860p target price for pharmaceuticals group Hikma after the firm's first-half results came in above forecasts, driven by a better-than-expected performance from the Injectables division. Group sales gained 34.8% to $532.3m in the first six months of the
Read moreAegis: UBS downgrades to neutral. Babcock: Espirito Santo downgrades to neutral. Balfour Beeatty: HB Markets downgrades to hold; Deutsche Bank downgrades to hold. BG Group: Morgan Stanley downgrades to equal weight. Capital Shopping Centres: Oriel Securities upgrades to hold. Carclo: N+1 Brewin
Read more- African Barrick up as China Gold shows interest - Markets continue to sift through global economic data - Wen sees 'growing room for policy operation' London's benchmark index was broadly flat on Thursday morning as investors continue to digest a raft of economic data that has been released over
Read moreCity sources predict the FTSE 100 will open up 17 points from yesterday's close of 5,833, boosted by hopes of further economic stimulus from central banks across the globe. Overnight China revealed that its foreign direct investment declined 8.7% to $7.6bn in July, compared to the same month the p
Read moreRevenue from generic drugs fell in the first half at Hikma Pharmaceuticals but branded products more than picked up the slack. Overall, revenue in the first half of 2012 rose 34.8% to $532.3m from $394.8m the year before, helped by contributions from recent acquisitions. Organic revenue growth was
Read moreAcquisitions are set to put a gloss on the interim results of pharmaceuticals firm Hikma on Thursday. Peel Hunt is expecting the group to report sales of more than $500m, up 25% on the first half of last year when, admittedly, results had been negatively affected by the so-called Arab Spring. Sale
Read moreAstraZeneca: Jefferies raises target from 2,975p to 3,100p, hold rating kept. Avon Rubber: Investec reiterates hold rating and 315p target. BTG: Jefferies maintains hold rating and 410p target. Cobham: Jefferies reiterates buy recommendation and 230p target; Investec keeps sell rating and 200p ta
Read moreRobert Bready, the Product Director of ASOS, the online clothes retailer, has slimmed down his stake in the firm with the sale of 44,299 shares. The transaction, which was carried out on Monday, earned Bready £724,289 and reduced his holding to 143,125 ordinary shares, equal to 0.18% of the total
Read moreSaid Darwazah, the Chief Executive Officer of Hikma Pharmaceuticals, the FTSE 250 multinational pharmaceutical group, has pocketed over one million pounds through the sale of company shares last week. Darwazah sold 195,447 shares at 649p each on June 15th for a total of £1,268,451, the company reve
Read more
Last checked at